Management of Hematologic Toxicity in Patients on Antipsychotic Medication

Assessment and Monitoring

Obtain complete blood count with differential to assess severity of neutropenia and thrombocytopenia, and monitor for signs of infection, which may indicate complications of neutropenia, in patients on olanzapine 1
Evaluate for other potential causes of cytopenias, such as medications or underlying hematologic disorders, in patients experiencing hematologic toxicity 2

For moderate to severe neutropenia, discontinue olanzapine immediately and monitor blood counts daily until recovery, and consider G-CSF for severe cases, according to the American Academy of Child and Adolescent Psychiatry 1, 2, 3
For moderate to severe thrombocytopenia, discontinue olanzapine immediately and monitor platelet counts until recovery, and consider thrombopoietin receptor agonists for severe cases if no marrow blasts are present, as recommended by the National Comprehensive Cancer Network 2, 3, 5
Provide antibiotic coverage if fever or signs of infection develop in patients with neutropenia, as suggested by the American Heart Association 4

Clozapine is generally not recommended as an alternative to olanzapine due to its known risk of agranulocytosis, according to the American Academy of Child and Adolescent Psychiatry 1

After resolution of cytopenias, consider cautious rechallenge at lower doses only if alternative treatments are limited, as suggested by the Annals of Oncology 2
If rechallenge is attempted, implement more frequent blood count monitoring, such as weekly for at least 8 weeks, as recommended by the American Academy of Child and Adolescent Psychiatry 1